Summary & Overview
HCPCS J2272: Morphine Sulfate (Fresenius Kabi) Injection, Up to 10 mg
HCPCS Level II code J2272 denotes an injectable formulation of morphine sulfate (Fresenius Kabi), up to 10 mg, that is specified as not therapeutically equivalent to J2270. Nationally, this code matters for accurate drug identification, billing differentiation among morphine products, and ensuring correct inventory and reimbursement practices for parenteral opioid therapy. Accurate use affects clinical documentation, payer adjudication, and drug-cost reporting.
Key payers examined include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find a concise overview of the code’s clinical context, common sites of service, and the implications for billing and claims processing. The publication outlines typical benchmarks and payment considerations, highlights any recent policy or coverage notes affecting injectable morphine coding, and explains how J2272 differs from similar HCPCS codes used for morphine formulations.
This summary equips billing managers, revenue cycle staff, and clinicians with the operational context needed to code encounters involving this specific morphine product, recognize payer coverage patterns, and interpret claim adjudication outcomes. Data not available in the input is identified where applicable.
Billing Code Overview
HCPCS Level II code J2272 represents an injection of morphine sulfate (Fresenius Kabi), not therapeutically equivalent to J2270, up to 10 mg. This code denotes a single-dose injectable opioid preparation supplied by the manufacturer Fresenius Kabi.
Service Type: Drug administration (injectable opioid medication)
Typical Site of Service: Outpatient clinic, hospital outpatient department, emergency department, or other ambulatory settings where parenteral opioid analgesia is administered.
Data not available in the input.
Clinical & Coding Specifications
Clinical Context
A typical patient is an adult presenting to an outpatient infusion center or hospital inpatient ward for parenteral analgesia management. The patient has moderate to severe acute pain (for example, post-operative pain after abdominal surgery or acute sickle cell pain crisis) or severe cancer-related pain uncontrolled by oral opioids. The clinical workflow: the treating clinician (anesthesiologist, hospitalist, emergency physician, or oncology specialist) orders J2272 for single-dose injection of morphine sulfate (Fresenius Kabi), up to 10 mg, indicating that this specific manufacturer’s product is not therapeutically equivalent to J2270. Nursing verifies allergies and baseline respiratory status, prepares the labeled syringe or vial, documents dose and route (typically intravenous push or slow IV bolus), administers the medication with appropriate monitoring (vital signs, pulse oximetry), and documents pain scores and any adverse effects. For outpatient procedures, billing is submitted by the facility using J2272; if administered during surgery or an ambulatory procedure, appropriate procedure and global period modifiers may be applied. Documentation includes indication, dose, lot number, route, time, patient response, and any monitored sedation or respiratory interventions.
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|
JW |